inclusion criteria: * pneumonic patients with sars-cov-2 infection confirmed to be positive by rt-pcr; and demonstrated moderate cases criteria (fever "measured temperature of at least 38 °c", lower respiratory symptoms "cough, shortness of breath" and imaging-confirmed pneumonia"). * female patients enrolled in the study should have no planned pregnancy for 6 months, after participating in the study, with administration of proper contraceptive measures within 30 days from the first therapeutic dose of the investigational drugs. * patients agreed to sign an informed consent to participate in the current study and that they would not participate in other clinical trials within 30 days from the last administration of the study drugs.

inclusion criteria: * pneumonic patients with sars-cov-2 infection confirmed to be positive by rt-pcr; and demonstrated moderate cases criteria (fever "measured temperature of at least 38 °c", lower respiratory symptoms "cough, shortness of breath" and imaging-confirmed pneumonia"). * female patients enrolled in the study should have no planned pregnancy for 6 months, after participating in the study, with administration of proper contraceptive measures within 30 days from the first therapeutic dose of the investigational drugs. * patients agreed to sign an informed consent to participate in the current study and that they would not participate in other clinical trials within 30 days from the last administration of the study drugs.

inclusion criteria: - pneumonic patients with sars-cov-2 infection confirmed to be positive by rt-pcr; and demonstrated moderate cases criteria (fever "measured temperature of at least 38 °c", lower respiratory symptoms "cough, shortness of breath" and imaging-confirmed pneumonia"). - female patients enrolled in the study should have no planned pregnancy for 6 months, after participating in the study, with administration of proper contraceptive measures within 30 days from the first therapeutic dose of the investigational drugs. - patients agreed to sign an informed consent to participate in the current study and that they would not participate in other clinical trials within 30 days from the last administration of the study drugs.

inclusion criteria: - pneumonic patients with sars-cov-2 infection confirmed to be positive by rt-pcr; and demonstrated moderate cases criteria (fever "measured temperature of at least 38 °c", lower respiratory symptoms "cough, shortness of breath" and imaging-confirmed pneumonia"). - female patients enrolled in the study should have no planned pregnancy for 6 months, after participating in the study, with administration of proper contraceptive measures within 30 days from the first therapeutic dose of the investigational drugs. - patients agreed to sign an informed consent to participate in the current study and that they would not participate in other clinical trials within 30 days from the last administration of the study drugs.